Archive: 2020

Fatty liver

21

Dec2020
The inextricable, well-documented link between the twin epidemics of nonalcoholic fatty liver disease, or NAFLD, and type 2 diabetes has raised alarms in the medical community. Click Here to read the article.
December 21, 2020clinic_doc
article-12-15-2020

15

Dec2020
Tuesday, December 15, 2020, 8:00 AM PST LOS ANGELES - National Research Institute (NRI) has announced today plans to participate  in an observer blinded, placebo-controlled clinical trial against COVID-19. The Phase 3 study is sponsored by Novavax, Inc. with NVX-CoV2373 vaccine candidate. Novavax, Inc. is a late-stage biotechnology company ... Read More
December 15, 2020clinic_doc
article-10-16-2020

16

Oct2020
NRI is excited to share these clinically relevant results for the efficacy and safety of Exenatide plus Dapagliflozin for patients with uncontrolled type 2 diabetes taking Metformin. We are proud to focus on diseases that affect our community and see great results such as these! https://care.diabetesjournals.org/content/43/10/2528.long  
October 16, 2020clinic_doc
article-10-8-2020

08

Oct2020
Take a look at our latest publication. We are honored to share the results from our involvement in this important T2DM study.  https://www.tandfonline.com/doi/pdf/10.1080/17446651.2020.1830759?needAccess=true
October 8, 2020clinic_doc
covid-media

22

Sep2020
NRI has been a proud contributor to the Pfizer COVID-19 vaccine trial! We believe that it is our obligation to help our communities find solutions to the COVID-19 crisis. We are honored when our patients agree to volunteer to participate and then take the time to provide us with valuable ... Read More
September 22, 2020clinic_doc
article

13

Aug2020
August 13, 2020clinic_doc
article-08-06-2020

06

Aug2020
Mark Leibowitz, M.D., Chief Medical Officer will lead National Research Institute’s study program with Eli Francisco, Senior Project Manager Potential participants can visit https://www.covidvaccinestudy.com/#about-the-study to learn more about local enrollment criteria Los Angeles, CA, August 06, 2020— National Research Institute (NRI) today announced plans to participate as a study site for, ... Read More
August 6, 2020clinic_doc
article-07-15-2020

15

Jul2020
Checkout this article published in the American Diabetes Association’s Diabetes Care issue regarding the comparison of “Ultra Rapid Lispro With Lispro in a Basal-Bolus Regimen in Patients With Type 2 Diabetes”. It’s an honor to share the involvement of Dr. Frias and NRI in this important study!   ... Read More
July 15, 2020clinic_doc
clinical-trials-day1

20

May2020
Clinical Trials Day is a special day to recognize the people who conduct clinical trials and thank them for improving public health. This day is also an opportunity to raise awareness about clinical trials. We'd like to thank and celebrate all clinical research professionals, including our very own at NRI, for ... Read More
May 20, 2020clinic_doc
article-05-11-2020

11

May2020
We are excited to share some great work from Dr. Frias and the NRI team regarding Dulaglutide’s significant results tied to A1C and weight reduction in diabetes. We are so proud of the valuable results from of our involvement with this Eli Lilly study. https://medicaldialogues.in/diabetes-endocrinology/news/higher-doses-of-dulaglutide-reduces-blood-sugar-and-weight-in-diabetes-65621
May 11, 2020clinic_doc
NRI CLINICS ARE CURRENTLY OPEN!
X